Future directions with taxane therapy

F. Cabral, E. Trimble, E. Reed, G. Sarosy

Research output: Contribution to journalArticlepeer-review

Abstract

The potential biochemical and genetic mechanisms by which a cell might experience a decreased sensitivity to taxanes and other drugs of this class are discussed in the first part of this article. The use of taxanes in the current gynecologic-oncologic clinical setting is reviewed with special consideration given to the pharmacokinetics of taxane in relation to dose intensity and length of administration.

Original languageEnglish (US)
Pages (from-to)21-41
Number of pages21
JournalHematology/Oncology Clinics of North America
Volume13
Issue number1
DOIs
StatePublished - Jan 1 1999
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Future directions with taxane therapy'. Together they form a unique fingerprint.

Cite this